申请人:Glaxo Wellcome Inc.
公开号:US05607929A1
公开(公告)日:1997-03-04
Compounds of formula (I) wherein n is 0, 1 or 2; and R.sup.1 and R.sup.2, which may be the same or different, each represent one or more ring substituent(s) selected from: hydrogen, hydroxy, halogen, cyano, nitro, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl or C.sub.1-6 alkoxy (where the alkyl or cycloalkyl moiety may be optionally substituted by one or more substituents selected from halogen atoms and hydroxyl groups); --NR.sup.4 R.sup.5 where R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen or C.sub.1-6 alkyl; --S(O).sub.m R.sup.6, where m is 0, 1, 2 or 3 and R.sup.6 represents hydrogen, C.sub.1-6 alkyl or C.sub.3-6 cycloakyl; --SO.sub.2 NR.sup.4 R.sup.5 where R.sup.4 et R.sup.5 are each as defined above; phenyl, phenylC.sub.1-3 alkoxy or phenylC.sub.1-3 alkyl where the phenyl group may be optionally substituted by one or more substituents independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, nitro, halogen and amino; and --CO.sub.2 H or --COR.sup.7 where R.sup.7 is C.sub.1-6 alkyl or C.sub.3-6 cycloalkyl; R.sup.3 represents hydrogen or C.sub.1-4 alkyl; and esters, salts and other physiologically functional derivatives thereof; show activity as antiviral agents, for example against HIV. Certain of the compounds are novel.
化合物的公式(I)其中n为0、1或2;而R1和R2,它们可以相同也可以不同,每个都代表一个或多个环取代基,所选取的基包括:氢、羟基、卤素、氰基、硝基、C1-6烷基、C3-6环烷基或C1-6烷氧基(其中烷基或环烷基部分可以被一个或多个卤素原子和羟基团取代);--NR4R5,其中R4和R5,它们可以相同也可以不同,每个都代表氢或C1-6烷基;--S(O)mR6,其中m为0、1、2或3,而R6代表氢、C1-6烷基或C3-6环烷基;--SO2NR4R5,其中R4和R5如上所定义;苯基、苯基C1-3烷氧基或苯基C1-3烷基,其中苯基团可以被一个或多个独立选择的基团取代,所选基团包括C1-6烷基、C1-6烷氧基、羟基、硝基、卤素和氨基;以及--CO2H或--COR7,其中R7为C1-6烷基或C3-6环烷基;R3代表氢或C1-4烷基;以及其酯类、盐类和其他生理功能衍生物,具有抗病毒活性,例如对HIV。其中某些化合物是新颖的。